logo.jpg
Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 10, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall® segment of the...
logo.jpg
Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR
July 13, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Patent bolsters intellectual property protection as Company’s partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK PHILADELPHIA, PA, July 13, 2021 (GLOBE...
logo.jpg
Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum
April 26, 2021 09:05 ET | Vallon Pharmaceuticals Inc.
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on April 29th at 10:30 AM ET PHILADELPHIA, PA, April 26, 2021 (GLOBE NEWSWIRE) -- Vallon...
logo.jpg
Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
April 13, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines...
logo.jpg
Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
March 29, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Pivotal data from lead program, ADAIR, expected in second half 2021 - Potential NDA filing for ADAIR in Q2 2022; targeting a ~$9 billion U.S. ADHD market1 - Novel abuse-deterrent platform...
logo.jpg
Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR
November 09, 2020 09:00 ET | Vallon Pharmaceuticals Inc.
Results demonstrated that ADAIR had slower absorption and lower early exposure, and was less desirable to recreational drug abusers on key measures of abuse liability compared to commercially...